GLP-1 and Breastfeeding: What the Label Actually Says

What the labels actually say — and it is not what gets repeated

If you are breastfeeding and weighing a GLP-1, start with the manufacturers' own prescribing information, because the guidance differs by product and formulation. The Wegovy injection, Ozempic injection and Zepbound labels call for an individual benefit-risk assessment during breastfeeding. The Wegovy label's Lactation section states there are no data on subcutaneously administered semaglutide or its metabolites in human milk, and then hands the judgment back to you and your clinician: the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the drug¹. Ozempic — the same molecule, different brand — says the same thing, adding that semaglutide was found in the milk of lactating rats at levels three- to twelve-fold lower than in maternal plasma, with unclear human relevance³. Zepbound goes further still and reports actual human milk measurements².

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

That is a risk-benefit statement, not proof that treatment is safe for every nursing mother. It also differs from the breastfeeding-not-recommended wording on the named oral products below.

The pills are the ones that say "don't nurse"

The Wegovy, Ozempic and Rybelsus tablet labels and the Foundayo label say breastfeeding is not recommended. The injection labels discussed here use individual benefit-risk wording. For the semaglutide tablets — Wegovy tablets, and the diabetes tablets sold as Ozempic and Rybelsus⁶ — the label identifies an additional concern involving the absorption enhancer. Oral semaglutide is formulated with salcaprozate sodium, or SNAC, an absorption enhancer — and the label states that SNAC and its metabolites are present in human milk. Because the enzymes that clear SNAC may be less active in infants than in adults, higher levels could accumulate in a neonate; and because injectable semaglutide, which contains no SNAC, is an available alternative, the label advises that breastfeeding is not recommended on the tablets¹.

Notice the shape of that reasoning. It is not "semaglutide is unsafe in milk." The same label reports that a clinical lactation study of the oral formulation found semaglutide concentrations below the lower limit of quantification in human milk¹. SNAC creates a formulation-specific concern. The label identifies an injectable alternative, but that does not establish that an injection is appropriate for an individual nursing mother.

Foundayo (orforglipron), the non-peptide pill, says it more plainly: "not recommended for nursing women." There are no human milk data, and in rats the drug reached milk at about three times the level in the mother's blood⁷. An oral product's warning does not by itself justify switching to an injection while nursing; the clinical need, feeding plan and remaining infant-safety uncertainty still need assessment.

The tirzepatide milk study most people do not know exists

The claim that there are simply no human data for tirzepatide is out of date. The Zepbound label carries a single-dose lactation study: eleven healthy lactating adults were given one 5 mg subcutaneous dose, and tirzepatide was undetectable in 164 of 171 milk samples. Across the seven samples where anything was measurable, the cumulative amount over a 28-day sampling window came to less than 0.02% of the maternal dose, with the last measurable concentration five days after the injection². That is a small study of one dose, not of ongoing treatment — but it is data, and it is printed in the document your prescriber is working from.

Where the actual caution lives

Pregnancy planning is a separate issue. The semaglutide instruction sits one section later, under reproductive potential: because of the potential for fetal harm and semaglutide's long half-life, discontinue Wegovy at least two months before planning a pregnancy¹, and Ozempic carries the identical two-month instruction³. If your feeding question is really a "how soon can I try for the next baby" question, that is the number that governs it, and our guide to postpartum weight loss and GLP-1 timing walks the sequence.

What LactMed adds

The NIH's Drugs and Lactation Database is the reference clinicians actually consult for feeding questions, and it is more directive than the labels are. Its semaglutide record, revised May 2026, states that semaglutide was not detectable in the milk of mothers taking it subcutaneously, that their breastfed infants experienced no adverse effects, and — plainly — that only injectable forms of semaglutide should be used during breastfeeding⁴. Its tirzepatide record is warmer on the feeding question and cooler on the drug: if a mother requires tirzepatide, that is not a reason to discontinue breastfeeding, but until more data become available it should be used with caution, especially while nursing a newborn or a preterm infant⁵.

Bring your feeding plan and your future-pregnancy plan to the first appointment, and ask your prescriber to read the Lactation section with you rather than paraphrase it from memory. Most compounded-GLP-1 telehealth intakes say nothing about breastfeeding at all, which is why it's worth naming the exception: HealthRX publishes an actual exclusion list that names "currently pregnant, planning pregnancy, or breastfeeding" alongside its other contraindications — genuine screening, even though the underlying label guidance above still applies regardless of which provider you use.

How much weight to put on all this

Low to moderate, and it is worth saying which parts are which. The named injection labels document an individual benefit-risk assessment; that wording does not establish infant safety. The reassurance underneath it is thinner: two small pharmacokinetic studies, eight mothers for semaglutide and eleven for tirzepatide, both measuring milk rather than babies, and both after single or short-term exposure rather than months of steady-state dosing. LactMed's semaglutide entry does report that those eight mothers' infants grew and developed normally, but that is maternal report over a few weeks, not a follow-up study. What would move this from "reassuring" to "established" is prospective infant outcome data during ongoing treatment, which nobody has published yet. Until then it is a shared decision, and the person to make it with is the clinician who knows your history.